Study of Weekly Genexol®-PM Plus Gemcitabine in Subjects With Recurrent and Metastatic Adenocarcinoma of the Pancreas

NCT02739633 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

47

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent Adenocarcinoma of the Pancreas
Metastatic Adenocarcinoma of the Pancreas

Interventions

DRUG: Genexol-PM
DRUG: Gemcitabine

Sponsor

Samyang Biopharmaceuticals Corporation